No, diltiazem and losartan are completely different medications with distinct mechanisms of action and clinical uses.
Diltiazem is a non-dihydropyridine calcium channel blocker, while losartan is an angiotensin II receptor blocker (ARB)—they belong to entirely different drug classes and work through fundamentally different mechanisms 1.
Key Differences
Mechanism of Action
Diltiazem works by blocking calcium channels in the heart and blood vessels, which:
- Slows AV node conduction and increases AV node refractoriness
- Reduces heart rate (negative chronotropic effect)
- Decreases cardiac contractility (negative inotropic effect)
- Causes vasodilation 2, 3, 4
Losartan blocks the angiotensin II type 1 (AT1) receptor, which:
- Prevents angiotensin II from causing vasoconstriction
- Reduces aldosterone secretion
- Does NOT affect heart rate
- Does NOT inhibit ACE or affect bradykinin
- Does NOT block calcium channels 1
Primary Clinical Uses
Diltiazem is primarily used for:
- Acute rate control in atrial fibrillation/flutter and supraventricular tachycardias (SVT) 2, 3, 4
- Hypertension (as a secondary agent) 5
- Hypertrophic cardiomyopathy with obstruction 6
- Typical dosing: 0.25 mg/kg IV bolus over 2 minutes for acute situations, or 120-360 mg daily orally for chronic management 7, 2
Losartan is primarily used for:
- Hypertension (as a first-line agent in appropriate patients) 5
- Heart failure with reduced ejection fraction
- Diabetic nephropathy
- Stroke prevention in patients with hypertension and left ventricular hypertrophy
- Typical dosing: 50-100 mg daily orally 5
Pharmacokinetics
Diltiazem:
- Acts directly on calcium channels
- Metabolized by CYP3A4 (is also a moderate CYP3A4 inhibitor)
- Has significant drug interactions 7, 2
Losartan:
- Undergoes first-pass metabolism to an active metabolite (14% conversion)
- The active metabolite is 10-40 times more potent than losartan itself
- Bioavailability approximately 33%
- Peak effect in 1-6 weeks for blood pressure control 1
Safety Profiles and Contraindications
Diltiazem should be avoided in:
- Decompensated heart failure with reduced ejection fraction
- AV block greater than first degree (without pacemaker)
- Severe hypotension
- Pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome)
- Combination with beta-blockers requires caution due to additive AV nodal blockade 2, 7, 2, 6, 5
Losartan should be avoided in:
- Pregnancy (teratogenic)
- Bilateral renal artery stenosis
- History of angioedema with ARBs
- Combination with ACE inhibitors or direct renin inhibitors
- Does NOT cause the bradycardia or heart block seen with diltiazem 5, 1
Clinical Performance Comparison
When directly compared for antiproteinuric effects in non-diabetic renal disease, losartan demonstrated superior efficacy to diltiazem (p<0.001), though this represents a specialized use case 8. However, for acute rate control in atrial fibrillation, diltiazem is far superior to alternatives, achieving target heart rate <100 bpm in 95.8% of patients by 30 minutes 9.
Common Pitfall
The most critical error would be substituting one medication for the other. If a patient requires rate control for atrial fibrillation or SVT, losartan will be completely ineffective—diltiazem or a beta-blocker is required 2, 3, 4. Conversely, if a patient needs renin-angiotensin system blockade for hypertension or heart failure, diltiazem does not provide this mechanism 5, 1.
These medications are not interchangeable and serve distinctly different therapeutic purposes in cardiovascular medicine.